Abbott Laboratories (NYSE:ABT) is among the stocks on Jim Cramer’s game plan as he shared his take on the market post Iran-U.S. ceasefire talks. Cramer called the stock “tricky,” as he commented:
I also want to hear from Abbott Labs, and this is tricky, okay? Its stock’s down an astounding 20% for the year after that last just so-so quarter, and a loss and a lawsuit about its special baby formula. But I don’t know if this really, if this stock really belongs on the 52-week low list. I mean, that said, if Abbott’s going to go higher, it’s going to have to give us a couple of reasons on the call.
A stock market graph. Photo by Alesia Kozik on Pexels
Abbott Laboratories (NYSE:ABT) develops and sells healthcare products, including generic medicines, diagnostic systems, nutrition brands, cardiovascular and diabetes care devices, and neuromodulation technologies. During the November 20, 2025, episode, Cramer discussed the company’s acquisition of Exact Sciences, as he stated:
This morning, Abbott Labs announced that it’s buying Exact Sciences, that’s the colorectal cancer screening company, for about $21 billion. It’s a 51% premium where it was trading before we started hearing talk of the deal. This transaction will be the largest healthcare deal in two years and the largest diagnostic acquisition ever. Exact Sciences has a great product… Of course, this kind of deal probably would’ve been blocked by Biden’s antitrust regulators if only because the FTC under Lina Khan seemed reflexively hostile to all mergers. But under Trump, it’ll probably sail through.
Now, normally, an acquired stock only gets hit hard if they’re paying… for the target with their own shares. But Abbott’s paying in cash, and it’s still dropped more than $6 over the past two days since the deal was reported. I think that’s crazy. Abbott has a big hole in its diagnostic business, and Exact Sciences would plug it. The rest of the business is doing quite well. So I think it’s a terrific time to do some buying, especially as once in the portfolio, it will accelerate Abbott’s growth rate.
While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center